Want to see SE:SYNACT full AI Analyst Report?
Top Page
SynAct Pharma AB
(SYNACT)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr17.50
▼(-9.98% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and sustained cash burn despite a low-debt balance sheet). Technicals add modest support with price above major moving averages and a positive MACD, while valuation remains unattractive/unclear given negative earnings and no dividend yield data.
Positive Factors
Low leverage
The extremely low debt burden gives SynAct greater financial flexibility than a highly leveraged development-stage company. A sizable equity base relative to assets can help absorb ongoing research spending and reduce immediate solvency pressure, although it does not eliminate future funding needs.
Negative Factors
No commercial revenue
SynAct lacks a recurring commercial revenue base, so its financial performance depends almost entirely on advancing clinical assets and eventually monetizing them. Until that occurs, the company cannot fund operations through product sales, leaving results highly sensitive to development progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The extremely low debt burden gives SynAct greater financial flexibility than a highly leveraged development-stage company. A sizable equity base relative to assets can help absorb ongoing research spending and reduce immediate solvency pressure, although it does not eliminate future funding needs.
Read all positive factors
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr972.50M
Dividend YieldN/A
Average Volume (3M)194.98K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue GrowthN/A
EPS Growth1.42%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding56,213,966
10 Day Avg. Volume98,425
30 Day Avg. Volume194,984
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
SynAct Pharma AB Business Overview & Revenue Model
Company Description
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently ...
How the Company Makes Money
SynAct Pharma is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not appear to have a marketed product generating recurring commercial sales; therefore, its business model is primarily funding-drive...
SynAct Pharma AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K |
| EBITDA | -113.35M | -116.52M | -15.40M | -222.70M | -105.71M | -76.62M |
| Net Income | -106.14M | -110.83M | -82.40M | -215.81M | -99.20M | -69.30M |
Balance Sheet | ||||||
| Total Assets | 208.24M | 220.52M | 270.52M | 228.02M | 142.60M | 38.37M |
| Cash, Cash Equivalents and Short-Term Investments | 14.23M | 53.41M | 61.21M | 62.40M | 108.25M | 24.00M |
| Total Debt | 929.00K | 1.81M | 1.88M | 637.00K | 2.06M | 3.09M |
| Total Liabilities | 36.57M | 50.23M | 56.35M | 51.83M | 16.08M | 17.50M |
| Stockholders Equity | 171.67M | 170.29M | 214.17M | 176.19M | 126.52M | 20.87M |
Cash Flow | ||||||
| Free Cash Flow | -82.67M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Operating Cash Flow | -117.21M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Investing Cash Flow | -13.89M | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K |
| Financing Cash Flow | 77.01M | 90.46M | 87.41M | 53.98M | 200.71M | 74.32M |
SynAct Pharma AB Technical Analysis
Negative
19.44
Price Trends
18.86
Negative
17.38
Negative
18.48
Negative
Market Momentum
-0.44
Positive
38.58
Neutral
21.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Negative. The current price of 19.44 is above the 20-day moving average (MA) of 18.56, above the 50-day MA of 18.86, and above the 200-day MA of 18.48, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 38.58 is Neutral, neither overbought nor oversold. The STOCH value of 21.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr411.64M | 2.15 | 63.09% | ― | ― | ― | |
56 Neutral | kr3.29B | -4.12 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr972.50M | -8.78 | -58.12% | ― | ― | 1.42% | |
45 Neutral | kr1.57B | -1.63 | -23.22% | ― | -195.45% | -223.22% | |
43 Neutral | kr1.46B | -2.95 | -99.58% | ― | -87.22% | -70.29% | |
43 Neutral | kr112.03M | -10.79 | -93.01% | ― | ― | 54.60% |
* Healthcare Sector Average
SE:SYNACT
SynAct Pharma AB
17.30
-4.60
-21.00%
SE:HNSA
Hansa Biopharma AB
32.36
-6.56
-16.86%
SE:BINV
BioInvent International AB
22.25
-5.90
-20.96%
SE:FLERIE
InDex Pharmaceuticals Holding AB
17.20
-19.68
-53.36%
SE:ACTI
Active Biotech AB
4.25
-8.81
-67.46%
SE:CANTA
Cantargia AB
1.46
-1.16
-44.17%
SynAct Pharma AB Corporate Events
SynAct Pharma Launches Global Investor and Partnering Push
Sep 22, 2026
SynAct Pharma plans an active presence at several investor and partnering conferences across Europe, the U.S., and Japan in September and October 2026. Chief executive Jeppe Øvlesen and chief business officer Mads Bjerregaard will present the...
WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
Sep 16, 2026
The World Health Organization has named SynAct Pharma’s oral pro-resolution therapy resomelagon as one of just six dengue drug candidates with sufficient efficacy data to merit further clinical development, and the only host-directed therapy...
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
Sep 7, 2026
SynAct Pharma has released further analysis from its Phase 2b ADVANCE study of resomelagon in treatment-naïve rheumatoid arthritis patients, reinforcing earlier positive EXPAND data and supporting Phase 3 development. The company plans to ref...
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
Sep 3, 2026
SynAct Pharma has disclosed that its chief executive officer, Jeppe Øvlesen, and chief scientific officer, Thomas Jonassen, have sold portions of their shareholdings in the company. The disposals were executed via their associated entities, Q...
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
Aug 28, 2026
SynAct Pharma will present new preclinical data on its Phase 3-ready resomelagon candidate at the 17th World Congress of Inflammation 2026 in Brazil, highlighting a distinct pro-resolution mechanism of action for inflammatory and infectious diseas...
SynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
Aug 20, 2026
SynAct Pharma has released its interim report for January to June 2026, highlighting research and development progress in inflammatory diseases and providing operational and financial updates to stakeholders. The report underscores the companyR...
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
Aug 19, 2026
SynAct Pharma has signed a term sheet with Brazilian drug maker Hipolabor Farmacêutica for a co-development and commercialization partnership around resomelagon to treat dengue and other viral infections in Brazil. The structure allows SynAct...
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
Aug 5, 2026
SynAct Pharma AB has secured a favorable ruling from the U.S. Patent Trial and Appeal Board on a patent application covering an immediate-release tablet formulation of its lead drug candidate, resomelagon. The decision confirms that developing a r...
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
Jul 20, 2026
SynAct Pharma has secured access to a new strategic financing facility of up to SEK 100 million and has initially drawn SEK 50 million through the issuance of convertible loans. The move strengthens the biotech’s balance sheet, broadens its ...
SynAct preclinical data point to osteoarthritis potential for resomelagon
Jul 9, 2026
SynAct Pharma AB reported early preclinical data indicating that its drug candidate resomelagon (AP1189) can reduce inflammation, joint damage and pain in a mouse model of osteoarthritis, a condition affecting hundreds of millions globally. The fi...
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
Jun 29, 2026
SynAct Pharma reported a marked increase in interest from pharmaceutical companies and specialized healthcare investors after presenting positive ADVANCE study results for its lead candidate resomelagon at the BIO International Convention in San D...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.